Atlas Trials

A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene

Clinical trial NCT00237185 · COMPLETED

Trial details

NCT number
NCT00237185
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)
Start date
2000-06-01
Primary completion
2013-06-01
Enrollment
148

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.